Therapeutic Focus


Helping patients who inspire and need us

We’ll never take impossible at face value.

For patients with rare immune-mediated diseases, adjusting to a new normal frequently means learning to live with compromise. At Momenta, we’re changing that.

We’re bringing new treatment options — and real help — to patients in underserved indications. We’re exploring dosing and delivery options that not only offer clinical benefit but improve quality of life. And we’re connecting patients who’ve felt isolated until now with a supportive advocacy community. Because we know that behind every seemingly impossible challenge is a patient with a story — and a future.

Our therapeutic areas of focus


Generalized Myasthenia Gravis (gMG)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Maternal Fetal Medicine

Hemolytic Disease of the Fetus and Newborn (HDFN)


Warm Autoimmune Hemolytic Anemia (wAIHA)
Immune Thrombocytopenic Purpura (ITP)

Myasthenia Gravis

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease which affects skeletal muscles that are responsible for eye movements, breathing, and moving parts of the body, resulting in muscle weakness and fatigue.

All muscle movements are triggered by nerve cells. In healthy muscles, nerve endings transmit signals that are received by muscle receptors to cause muscle contraction. But in MG, the immune system mistakenly attacks those receptors by producing anti-receptor antibodies (most commonly acetylcholine receptor [AChR] or muscle-specific kinase [MuSK] antibodies) that can block or destroy these muscle receptors, preventing the signals from effectively reaching the muscles. Over time, this may lead to symptoms such as limb weakness, drooping eyelids, and double vision, as well as difficulties with chewing, swallowing, speech, and breathing.

While many patients with MG may be managed with current therapies, some patients may 1) fail to respond adequately despite multiple therapies, 2) not tolerate these therapies, and/or 3) have conditions that do not allow the use of these therapies. These patients may continue to experience profound muscle weakness and severe disease symptoms that limit their functions and their quality of life. Research is needed to develop the new treatment options for patients with MG.

Learn about how Momenta’s investigational drug nipocalimab works to reduce pathogenic autoantibodies, which disrupt muscle receptors and neuromuscular junctions in MG, leading to muscle weakness and fatigue. Learn more >

Hemolytic Disease of the Fetus and Newborn

Hemolytic disease of the fetus and newborn (HDFN) is an immune system disorder that occurs when the blood types of a mother and fetus are incompatible.

Blood Types and Blood Group Proteins

In addition to the four major blood types (A, B, AB, and O), blood types are also determined by the presence or absence of something called a blood group protein, called an antigen.

When a woman becomes pregnant, the baby inherits genes from both parents, including blood type and blood group antigens. If the mother’s blood type has a negative antigen and the baby inherits a positive antigen blood type from the father, the mother’s immune system may begin making antibodies to attack the baby’s “foreign” red blood cells.

Typically, the immune system response is not strong enough to affect the first pregnancy. However, future pregnancies involving incompatible blood group antigens will often trigger a much stronger response. This immune response can lead to a number of serious health complications for the fetus, including severe anemia, jaundice, congestive heart failure, edema, and death.

Prevention and Treatment

While many cases of HDFN are largely preventable, those who require treatment for severe HDFN can be faced with intensive and invasive procedures (such as intrauterine transfusions), which may be associated with significant complications. What’s needed are new non-invasive, safe, and effective treatment options.

Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm autoimmune hemolytic anemia (AIHA) is a rare anemia caused by a malfunction of the immune system. The immune system releases antibodies that mistakenly attach to healthy red blood cells and destroy them. Anemia is the result when the body does not have enough red blood cells.

In most people, the anti-RBC antibodies, called IgG antibodies, are active in normal warm body temperature, which is why it is called ‘warm’ autoimmune hemolytic anemia (wAIHA).

Warm antibody hemolytic anemia can be primary, which means there is no other cause or secondary where the anemia is due to/complications by another disease or condition, like lupus or a blood cancer.